Strong Evidence Increases Case Value Timothy Felice explains that the strength of evidence directly impacts the outcome of a case. He emphasizes that while lawyers guide and advise, the final decision always belongs to the client, making clear communication and honest recommendations essential. Click the bio link to listen to the full episode. bio.link/timothyfelice #StrongEvidence #CaseValue #LegalStrategy #PersonalInjuryLaw #InjuryLawyer #Litigation #EvidenceMatters #LegalInsights

ಪ್ರಜ್ವಲ್ ರೇವಣ್ಣ ವಿರುದ್ಧ ಸಾಕ್ಷಿಗಳಿವೆ, ಬೇಲ್ ಕೊಡಲ್ಲ: ಹೈಕೋರ್ಟ್ #HighCourt #Bail #PrajwalRevanna #StrongEvidence kannada.asianetnews.com/stat…

Extra-Judicial Confession Can't Be Strong Evidence If Not Supported by Other Evidence On Record. For further information, refer to this Article By Adv.Rajveer Singh (bit.ly/4g7DC2r). #Judicial #confession #strongevidence #legalupdates #legalnews #SoOLEGAL #legalhelp

India-Canada: ટ્રુડોની ફરી ખુલી પોલ, નિજ્જર કેસને લઈ પોલીસ કમિશનરનું મોટું નિવેદન #CanadaPolice #CanadaPoliceCommissioner #NijjarMurderCase #StrongEvidence #Indian #IndiaCanadaRelations #JustinTrudeau #SandeshNews sandesh.com/world/india-cana… વધુ સમાચાર વાંચવા ડાઉનલોડ કરો સંદેશ ન્યૂઝ એપ : sandesh.com/d

"...It is possible that simple profit-taking is the motive behind this 21% reduction in Berkshire's stake in Bank of America over the last 10 weeks... ....but there may be something far more menacing behind Buffett's aggregate $9 billion in sales of BofA stock." "...He's frequently opined that investors should never bet against America, which is precisely why you won't see him or his investing lieutenants, Ted Weschler and Todd Combs, short-selling stocks or buying put options. However, Buffett's optimism isn't blind. Although he fully understands that economic cycles aren't linear and the U.S. economy spends a disproportionate amount of time expanding, relative to contracting, he's not willing to chase stocks higher if he doesn't see value or can't locate plain-as-day bargains. Over the previous seven quarters (Oct. 1, 2022 to June 30, 2024), Buffett has been a decisive net seller of equities to the tune of $131.6 billion. Although Berkshire won't file its 13F with the SEC for the September-ended quarter until Nov. 14, SEC Form 4 filings provide strongevidence that this net selling activity is set to continue for an eighth straight quarter. On Sept. 24, Buffett's company filed a Form 4 showing that roughly 21.56 million shares of Bank of America(NYSE: BAC), worth about $862.7 million, were sold. However, this sale of Berkshire Hathaway's third-largest holding by market value wasn't an isolated incident. Since July 17, Buffett has sold shares of Bank of America during 33 separate trading sessions, with the cumulative market value of these sales nearing $9 billion. A position that once stood at more than 1.03 billion shares owned has been whittled down to 814.35 million shares, as of Sept. 24..." Sept 9, 2024 fool.com/investing/2024/09/0… Sept 28, 2024 fool.com/investing/2024/09/2…

Strongevidence that #Ethiopia committedgenocide in #Tigray war:Report @NewlinesInst report says #Ethiopia and allies [#Eritrea and #Amhara] had ‘intent to destroy #Tigrayans as an ethnic group’and calls for prosecution at @CIJ_ICJ. @AJEnglish @RouhanaMarie aljazeera.com/news/2024/6/4/…

Markolin's thread is a smear campaign against USRTK followed by this laughable defense of PO. The fact that Holmes amplified the thread is #StrongEvidence that he has no defense for his actions.

NO HONEST SCIENTIST WOULD ALLOW THEIR NAME TO BE ON A PAPER THAT CONTAINS THE LAST SENTENCE OF THIS PARAGRAPH. #StrongEvidence #RetractProximalOrigins "While the analyses above suggest that SARS-CoV-2 may bind human ACE2 with high affinity, computational analyses predict that the interaction is not ideal and that the RBD sequence is different from those shown in SARS-CoV to be optimal for receptor binding. Thus, the high-affinity binding of the SARS-CoV-2 spike protein to human ACE2 is most likely the result of natural selection on a human or human-like ACE2 that permits another optimal binding solution to arise. This is STRONG EVIDENCE that SARS-CoV-2 is not the product of purposeful manipulation."

Kristian Andersen has repeatedly stated the goal of the authors of Proximal Origins was to falsify the hypothesis that SARS-CoV-2 was lab generated (see, for example, his Congressional testimony). He has further stated this is part of the "scientific method." However, the arguments presented in Proximal Origins are embarrassingly bad, raising the possibility there was a deliberate attempt to suppress the lab origin hypothesis. Consistent with this proposal, correspondence between the Proximal Origin authors before Proximal Origins was written, during the writing/revision stage, and after publication of the manuscript, indicate the authors were deliberately attempting to suppress the lab origin hypothesis. Taken together, the text of Proximal Origins combined with the private messages between authors provide #StrongEvidence that Proximal Origins was the product of a deliberate attempt to suppress the lab origin hypothesis. As an aside, I might be mistaken, but didn't you miss some of the discussion because you had to attend to dinner guests? (perhaps that was someone else, but I thought it was you)

Director @YNatsis on stage today at KCE 20th Anniversary symposium: how is the #pharma ecosystem changing? What is the legacy of the #pandemic and global #permacrises? What role for the #EUPharmaRevision: a revolution for #StrongEvidence based decisions or much of the same?

Thank you #ISPOREurope for having me! Important to emphasise #StrongEvidence for better & affordable #medicines. We published our detailed ESIP-MEDEV proposals on the new #pharma package last week already: shorturl.at/bcrRU

The #EUPharmaRevision, discussed today at #IPSOREurope plenary @YNatsis on stage, voicing #healthcare payers’ priorities for #StrongEvidence, #AffordableAccess, #SustainableHealthcare Key words: 🔹sustainability 🔸social contract 🔹societal needs 📩 bit.ly/40uQ8lW

Starting the day at #ISPOREurope plenary 2 Director @YNatsis on stage discussing the #EUPharmaRevision ‘the good, the bad or the…’ Find out proposals for #StrongEvidence, #AffordableAccess in our ESIP-MEDEV position paper 📩 bit.ly/40uQ8lW

Today we publish our ESIP & MEDEV proposals to improve the #EUPharmaLegislation towards 🔸 producing #StrongEvidence for informed decision-making & 🔹 promoting #Competition for #AffordableAccess & #SustainableHealthcare Find our position paper: bit.ly/40uQ8lW

Jack Smith doesn't even have to open his mouth to convict TFIDIOT45... #StrongEvidence

Towards the #EUPharmaRevision 🔸 #AffordableAccess 🔹#StrongEvidence for informed decision making 🎯Rationalising rather than rationing #pharmaceutical #expenditure @ESIP_EU @YNatsis

Attending @beuc event hosted by @woelken on #EUPharma, timely ahead of the #EUPharmaRevision tomorrow Director @YNatsis: high #prices are an escalator phenomenon. We need to rebalance the system to support affordable #access #Affordability #StrongEvidence

Important development. Unreasonably high prices combined with poor, incomplete datasets jeopardise #patients' #accesstomedicines. I fear there will be more of these very tough decisions in the future. #EUPharmaRevision #StrongEvidence

At @TLV_nyheter stakeholder conference. Key word = #affordability Most possible #health meaning: best possible #access, #StrongEvidence, #healthcare systems #sustainability

We are pleased to see strong MEP support to #sustainable #access to #affordable medicines: 🔸Assess & balance #Incentives 🔸Promote #StrongEvidence based treatment 🔸Foster #Competition Congratulations @MetzTilly for leading this initiative towards the #EUPharmaRevision